文献速递心律失常心力衰竭与心肌病

依普利酮减少房颤负荷但不阻止心房电重构

Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

该研究在34只心房快速起搏绵羊中比较每日口服依普利酮(n=19)与安慰剂(n=15)的效果,发现依普利酮减轻左房扩张和纤维化、降低房颤负荷与诱发性,并在26%动物中延长至持续性房颤的时间,但未阻止电重构或房颤持续。

要点

  • 依普利酮减轻心房结构重构(扩张、纤维化、肥大),降低房颤负荷。
  • 依普利酮未改变房颤诱导的电重构(优势频率、离子通道密度)。
  • 依普利酮仅在26%动物中延长至持续性房颤的时间,未防止房颤持续。

核心结论

  • 在绵羊模型中,依普利酮减轻纤维化和心房扩张,改变房颤诱发性与复杂性,并在26%动物中延长至持续性房颤的时间,但不阻止房颤诱导的电重构或房颤持续。

研究设计与样本

  • 随机对照研究,34只心房快速起搏(13±1周)绵羊,每日口服依普利酮(n=19)或安慰剂(n=15),终点为连续7天持续性房颤(n=29)或完成23周起搏(n=5)。

主要发现

  • 依普利酮显著降低房颤进展中左房扩张的增加速率。
  • 依普利酮组心房平滑肌肌动蛋白、III型胶原表达、间质纤维化和细胞肥大均低于安慰剂组。
  • 依普利酮未改变安慰剂组中房颤诱导的优势频率增加速率和离子通道密度。
  • 依普利酮在26%动物中延长至持续性房颤的时间,并降低颤动传导程度、房颤诱发性及房颤负荷。

临床怎么用

  • 依普利酮可能通过靶向结构重构减少房颤负荷,但需联合阻止电重构以预防房颤持续。

局限性

  • 研究为绵羊模型,样本量34只,结果外推至人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown. OBJECTIVES: This study hypothesized that by reducing atrial dilation and fibrosis in the absence of heart failure, EPL also reduces AF burden and prevents AF perpetuation. METHODS: The authors conducted a randomized controlled study in 34 sheep that were atrially tachypaced (13 ± 1 week). They compared daily oral EPL (n = 19) versus sugar pill (SP) treatment (n = 15) from the start of tachypacing. The endpoint was a continuous 7-day stretch of persistent AF (n = 29) or completion of 23 weeks tachypacing (n = 5). RESULTS: EPL significantly reduced the rate of left atrial dilation increase during AF progression. Atria from EPL-treated sheep had less smooth muscle actin protein, collagen-III expression, interstitial atrial fibrosis, and cell hypertrophy than SP-treated sheep atria did. However, EPL did not modify the AF-induced increase in the rate of dominant frequency and ion channel densities seen under SP treatment, but rather prolonged the time to persistent AF in 26% of animals. It also reduced the degree of fibrillatory conduction, AF inducibility, and AF burden. CONCLUSIONS: In the sheep model, EPL mitigates fibrosis and atrial dilation, modifies AF inducibility and AF complexity, and prolongs the transition to persistent AF in 26% of animals, but it does not prevent AF-induced electrical remodeling or AF persistence. The results highlight structural remodeling as a central upstream target to reduce AF burden, and the need to prevent electrical remodeling to avert AF perpetuation.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Takemoto Y, Ramirez RJ, Kaur K, et al. Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling. J Am Coll Cardiol. 2017. PMID: 29216985. doi:10.1016/j.jacc.2017.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。